Athersys, Inc (NASDAQ:ATHX) Gets Downgraded

777

Dallas, Texas 03/26/2014 (FINANCIALSTRENDS) – Zacks lowered Athersys, Inc (NASDAQ:ATHX) shares from a “neutral” to an “underperform” rating in the research report that was released to investors. Currently, Zacks has price target of $3.40 on the stock. Athersys, Inc (NASDAQ:ATHX) last announced the company’s earnings results on 13 March . It reported earnings per share of $0.15 for the quarter, which missed the average projection of ($0.11) by $0.04. Athersys, Inc (NASDAQ:ATHX) reported revenue of $0.92M for the quarter, in comparison to the average projection of $1.81 million. Athersys, Inc (NASDAQ:ATHX)’s revenue for that quarter dropped 59.8% on a y-o-y basis. On an average, analysts project that Athersys, Inc (NASDAQ:ATHX)will post earnings per share of $-0.31 for the current financial year.

In separate Athersys, Inc (NASDAQ:ATHX) news, William Lehmann Jr, the company’s Chief Operating Officer, offloaded 25,000 shares of Athersys, Inc (NASDAQ:ATHX) stock in the transaction that was dated Thursday, March 20th. These shares were sold-off at an average- price of $3.62, and the total transaction value was $90,500.00. This sale was disclosed in the legal-filing with the SEC.

Athersys Inc. is a bio pharma company that is involved in the field of regenerative-medicine. In the year that ended Dec 31, 2011 Athersys, Inc (NASDAQ:ATHX) is developing the platform product, MultiStem, which is an allogeneic stem-cell product that has now been evaluated in 2 completed Phase-I clinical trials & as of Dec 31, 2011, is now being evaluated in 2, ongoing Phase-II clinical trials. Athersys, Inc (NASDAQ:ATHX)’s clinical development-programs are now focused on the treatment of inflammatory & immune disorders, and neurological conditions, and cardiovascular disease, as well as other conditions.

Athersys, Inc (NASDAQ:ATHX) is also involved in developing small molecule-therapies in treating obesity & many other conditions. In 2011, Athersys, Inc (NASDAQ:ATHX)is focused on development of potent, highly-selective compounds that can act through the stimulation of the specific-receptor in the brain that effectively controls appetite.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.